A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy-Reference-Cited by-同舟云学术

A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy

Published:2012-08 Issue:4 Volume:14 Page:
ISSN:1465-542X
Container-title:Breast Cancer Research
language:en
Short-container-title:Breast Cancer Res

Author:

Fan Xuejun,Brezski Randall J,Fa Ming,Deng Hui,Oberholtzer Allison,Gonzalez Anneliese,Dubinsky William P,Strohl William R,Jordan Robert E,Zhang Ningyan,An Zhiqiang

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/bcr3240.pdf

Reference49 articles.

1. Albanell J, Baselga J: Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer. Drugs Today (Barc). 1999, 35: 931-946.

2. Spector NL, Blackwell KL: Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2009, 27: 5838-5847. 10.1200/JCO.2009.22.1507.

3. Clynes RA, Towers TL, Presta LG, Ravetch JV: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000, 6: 443-446. 10.1038/74704.

4. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, Neri TM, Ardizzoni A: Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol. 2008, 26: 1789-1796. 10.1200/JCO.2007.14.8957.

5. Wilken JA, Maihle NJ: Primary trastuzumab resistance: new tricks for an old drug. Ann N Y Acad Sci. 2010, 1210: 53-65. 10.1111/j.1749-6632.2010.05782.x.

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Developability considerations for bispecific and multispecific antibodies;mAbs;2024-08-27

2. Assessing Physicochemical Stability of Monoclonal Antibodies in a Simulated Subcutaneous Environment;Journal of Pharmaceutical Sciences;2024-07

3. The proteolytic airway environment associated with pneumonia acts as a barrier for treatment with anti-infective antibodies;European Journal of Pharmaceutics and Biopharmaceutics;2024-02

4. High-fidelity large-diversity monoclonal mammalian cell libraries by cell cycle arrested recombinase-mediated cassette exchange;Nucleic Acids Research;2023-11-06

5. Barriers for orally inhaled therapeutic antibodies;Expert Opinion on Drug Delivery;2023-08-03